FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.
研究ライブラリに戻る
liraglutideatrial natriuretic peptiderelaxin mimeticsUcn1adropinKED tripeptideAEDR tetrapeptide

Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.

May 17, 2026
Share

元の論文

Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.

Khavinson Vladimir et al.Cells2022
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

Harnessing Peptides to Combat Age-Related Cardiovascular Diseases

Published: May 17, 2026 | Source: Cells (2022) | Category: liraglutide, atrial natriuretic peptide, relaxin mimetics, Ucn1, adropin, KED tripeptide, AEDR tetrapeptide

Overview

A recent review in the journal Cells highlights how peptides can play a crucial role in regulating senescence-associated secretory phenotype (SASP) and inflammaging, which are key contributors to age-related cardiovascular diseases. This research underscores the potential of specific vasoprotective polypeptides as therapeutic agents for managing conditions like atherosclerosis and myocardial infarction.

Study Background

As people age, cells in the body undergo senescence—a state where they stop dividing but remain metabolically active, often releasing inflammatory molecules that contribute to chronic inflammation (inflammaging). This process is linked to various cardiovascular diseases. Researchers have long sought ways to mitigate these effects and improve heart health in older individuals. The review synthesizes existing literature on peptides' role in regulating SASP-related molecules in the cardiovascular system.

What the Research Found

The study found that senescent cells of the cardiovascular system exhibit altered synthesis of proteins such as p16, p21, and p53, which are known to inhibit cell proliferation. Additionally, these cells produce cytokines like IL-1α, IL-6, TNFα, and TGFβ1, all of which contribute to inflammaging. The review also identified several peptides that can regulate the synthesis of molecules involved in SASP and inflammaging, including liraglutide, atrial natriuretic peptide (ANP), relaxin mimetics, Ucn1, adropin, KED tripeptide, and AEDR tetrapeptide. These peptides have shown promise in modulating the inflammatory response and potentially reversing some aspects of cellular senescence.

What This Means for Peptide Users

For those using or considering peptide therapy, this research suggests that certain vasoprotective polypeptides might offer a new avenue to manage age-related cardiovascular conditions. However, it is important to note that while these peptides show potential in laboratory settings and animal models, their efficacy and safety in human clinical trials remain to be fully established.

Limitations and Caveats

As a review paper, the study does not present any new experimental data but rather synthesizes existing literature. This means that definitive conclusions about the therapeutic value of peptides cannot yet be drawn based on this work alone. Additionally, while promising results have been observed in preclinical studies, more research is needed to understand how these peptides might function in human patients and what potential side effects they may carry.

How This Compares to Previous Research

This review aligns with previous findings that highlight the importance of SASP and inflammaging in cardiovascular health. However, it uniquely emphasizes the role of peptides as potential regulators of these processes. Other studies have focused on different therapeutic approaches or broader mechanisms without specifically targeting peptide-based interventions for cardiovascular diseases.

Our Analysis

PeptideVault views this review positively, recognizing its contribution to understanding how specific peptides might influence SASP and inflammaging in cardiovascular cells. However, we also acknowledge the need for more rigorous clinical trials to validate these findings before recommending any changes in treatment protocols. The research provides a solid foundation for future studies but falls short of providing conclusive evidence for immediate therapeutic application.

Key Takeaways

  • Peptides show promise as regulators of SASP and inflammaging in cardiovascular cells.
  • Specific vasoprotective polypeptides like liraglutide, ANP, relaxin mimetics, Ucn1, adropin, KED tripeptide, and AEDR tetrapeptide are highlighted for their potential therapeutic benefits.
  • Further clinical research is necessary to confirm the safety and efficacy of these peptides in human patients.

Original Source

Citation: Khavinson Vladimir, Linkova Natalia, Dyatlova Anastasiia et al. (2022). Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.. Cells. DOI: 10.3390/cells12010106

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

関連研究

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。